Antibody-drug conjugate

SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences

Retrieved on: 
Tuesday, November 16, 2021

SOTIO will obtain rights to deploy LCBs ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens.

Key Points: 
  • SOTIO will obtain rights to deploy LCBs ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens.
  • The deal includes upfront and near-term milestones worth up to $29.5 million, subject to exercise of the options and achievement of success-based milestones.
  • At SOTIO we are building an innovative pipeline of ADC programs and plan IND filing for our lead program SOT102 by the end of 2021.
  • The licensing agreement with our new, experienced partner LegoChem allows us to broaden our oncology pipeline with additional programs and solid tumor targets.

Applied BioMath, LLC Awarded Top Biosimulation Solution Company by Pharma Tech Outlook

Retrieved on: 
Tuesday, November 9, 2021

Applied BioMath opened their doors in 2013, with the goal of revolutionizing drug invention by applying biosimulation approaches to inform R&D decisions for biotechnology and pharmaceutical companies.

Key Points: 
  • Applied BioMath opened their doors in 2013, with the goal of revolutionizing drug invention by applying biosimulation approaches to inform R&D decisions for biotechnology and pharmaceutical companies.
  • "Biosimulation approaches enable quantitative decision making that impacts go/no-go decisions, strategy, and reduces risk years before going into the clinic," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.
  • To read the full Pharma Tech Outlook article, please visit https://www.appliedbiomath.com/our-science/mathematical-approaches-predi... .
  • Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

DGAP-News: Heidelberg Pharma Participates at Various Conferences

Retrieved on: 
Thursday, October 28, 2021

Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer.

Key Points: 
  • Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer.
  • Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany.
  • Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments

Retrieved on: 
Tuesday, October 12, 2021

Created in collaboration with leading pharmaceutical and clinical scientists, this novel panel is designed to provide molecular insights into important biological questions and challenges of oncology therapies.

Key Points: 
  • Created in collaboration with leading pharmaceutical and clinical scientists, this novel panel is designed to provide molecular insights into important biological questions and challenges of oncology therapies.
  • View the full release here: https://www.businesswire.com/news/home/20211012005285/en/
    Image of an Antibody Drug Conjugates (ADCs) enabling the targeted delivery of highly potent cytotoxic compounds to treat cancer.
  • The new panel provides for customizable ADC content to address complex questions critical for the success of Antibody Drug Conjugates throughout discovery, pre-clinical and clinical development.
  • NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

GeneQuantum announces two key leadership appointments

Retrieved on: 
Thursday, September 16, 2021

Their joining marks a concrete step forward in our strategic planning of establishing and expanding a world-class clinical and regulatory affairs team.

Key Points: 
  • Their joining marks a concrete step forward in our strategic planning of establishing and expanding a world-class clinical and regulatory affairs team.
  • Their extensive expertise and excellent leadership capability are crucial for the success of the company.
  • They commented, " GeneQuantum has the world's leading Antibody-Drug-Conjugate (ADC) iLDC platform, as well as a rich and innovative pipeline based on this platform.
  • We are very happy to join GeneQuantum in this critical moment, when the company is growing quickly with many products entering the IND and clinical stage.

PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

Retrieved on: 
Friday, September 10, 2021

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (Nasdaq: VOR) (Vor) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, Vors lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (Nasdaq: VOR) (Vor) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, Vors lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).
  • Vor remains on track to report VOR33s initial clinical data in the first half of 2022.
  • The full text of the announcement from Vor is as follows:
    CAMBRIDGE, Mass., Sept. 09, 2021 Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Companys lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).
  • Therapeutic candidates receiving Fast Track designation may be eligible for priority review and accelerated approval if certain conditions are met.

DGAP-News: Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences

Retrieved on: 
Thursday, September 9, 2021

Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences

Key Points: 
  • Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences
    The issuer is solely responsible for the content of this announcement.
  • Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences
    Ladenburg, Germany, 9 September 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present the company and its proprietary ATAC technology at several upcoming scientific and investor conferences.
  • Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma, will give a corporate presentation at the virtual global investor conference.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

VOR33 Granted U.S. FDA Fast Track Designation for AML

Retrieved on: 
Thursday, September 9, 2021

CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Companys lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).

Key Points: 
  • CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Companys lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).
  • Fast Track designation is intended to facilitate development and expedite review of products designed to treat serious and life-threatening conditions with unmet medical needs.
  • Therapeutic candidates receiving Fast Track designation may be eligible for priority review and accelerated approval if certain conditions are met.
  • Forward-looking statements in this press release include the Companys statements regarding the potential efficacy of VOR33, potential benefits VOR33 may receive in connection with its Fast Track designation and reporting initial clinical data from the VOR33 Phase 1/2a clinical trial in the first half of 2022.

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

Retrieved on: 
Monday, September 6, 2021

(hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.

Key Points: 
  • (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.
  • In recent years, immunotherapeutic antibody drugs targeting PD-1 and PD-L1 (representing immune checkpoint inhibitors) have revolutionized cancer therapy.
  • Linker stability is extremely important in the field of antibody immune agonist conjugates.
  • GeneQuntum focuses on the development of differentiated innovation products through in-house research and development and diversified external research and development cooperation.

GeneQuantum announces Dr. Yi Xia as Senior Vice President of Statistics and Data Science

Retrieved on: 
Monday, August 30, 2021

SUZHOU, China, Aug. 29, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmaceutical company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announces the appointment of Dr. Yi Xia as Senior Vice President of Statistics and Data Science to further strengthen the company's management team.

Key Points: 
  • SUZHOU, China, Aug. 29, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmaceutical company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announces the appointment of Dr. Yi Xia as Senior Vice President of Statistics and Data Science to further strengthen the company's management team.
  • "We are delighted to welcome Dr. Xia to join our management team," Dr.
  • Dr. Yi Xia received his Ph.D. in Statistics from Rutgers University.
  • Dr. Xia has rich experience in biostatistics, data management, clinical trial design, NDA submissions.